NASDAQ:SNGX - Soligenix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.58 0.00 (0.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.58
Today's Range$1.55 - $1.59
52-Week Range$1.54 - $3.70
Volume26,123 shs
Average Volume34,217 shs
Market Capitalization$13.81 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56

About Soligenix (NASDAQ:SNGX)

Soligenix logoSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio2.16
Quick Ratio2.16

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.43 million
Price / Sales2.54
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book3.36

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,140,000.00
Net Margins-149.71%
Return on Equity-182.10%
Return on Assets-105.34%

Miscellaneous

Employees18
Outstanding Shares8,740,000

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Friday, May, 11th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.02. The biopharmaceutical company earned $1.10 million during the quarter. Soligenix had a negative net margin of 149.71% and a negative return on equity of 182.10%. View Soligenix's Earnings History.

When is Soligenix's next earnings date?

Soligenix is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Soligenix.

What price target have analysts set for SNGX?

2 brokers have issued 12-month price objectives for Soligenix's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Soligenix's stock price to reach $4.00 in the next year. View Analyst Ratings for Soligenix.

Who are some of Soligenix's key competitors?

Who are Soligenix's key executives?

Soligenix's management team includes the folowing people:
  • Dr. Christopher J. Schaber Ph.D., Chairman, CEO & Pres (Age 52)
  • Ms. Karen R. Krumeich, CFO, Sr. VP, & Corp. Sec. (Age 64)
  • Dr. Oreola Donini Ph.D., Chief Scientific Officer & Sr. VP (Age 46)
  • Dr. Richard C. Straube M.D., MSc., Chief Medical Officer & Sr. VP (Age 66)
  • Mr. Adam T. Rumage, VP of Project Management & Regulatory Affairs

Has Soligenix been receiving favorable news coverage?

News stories about SNGX stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Soligenix earned a media sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $1.58.

How big of a company is Soligenix?

Soligenix has a market capitalization of $13.81 million and generates $5.43 million in revenue each year. Soligenix employs 18 workers across the globe.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]


MarketBeat Community Rating for Soligenix (SNGX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Soligenix (NASDAQ:SNGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Soligenix in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 153.16%. The high price target for SNGX is $5.00 and the low price target for SNGX is $3.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.503.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$3.85$5.25
Price Target Upside: 153.16% upside47.06% upside73.42% upside172.02% upside

Soligenix (NASDAQ:SNGX) Consensus Price Target History

Price Target History for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Maxim GroupSet Price TargetBuy$5.00LowView Rating Details
3/16/2018HC WainwrightSet Price TargetHold$3.00LowView Rating Details
9/7/2016AegisInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Soligenix (NASDAQ:SNGX) Earnings History and Estimates Chart

Earnings by Quarter for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.27)($0.27)($0.27)

Soligenix (NASDAQ SNGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2018N/AView Earnings Details
5/11/2018Q1 2018($0.29)($0.27)$1.10 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.3230)($0.17)$1.36 million$1.82 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.3230)($0.41)$1.43 million$1.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.30)($0.32)$1.30 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.85)($0.17)$2.90 million$1.70 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.43)$2.50 million$3.00 millionViewN/AView Earnings Details
8/11/2016Q2 2016($0.90)($0.20)$2.50 million$3.16 millionViewN/AView Earnings Details
5/12/2016Q1 2016($0.40)$2.63 millionViewN/AView Earnings Details
3/24/2016Q1($0.06)($0.04)$1.00 million$2.97 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.90)($0.40)$3.00 million$3.90 millionViewN/AView Earnings Details
8/12/2015($0.10)($0.15)$1.00 million$1.10 millionViewN/AView Earnings Details
5/14/2015Q1 2015($1.00)($0.70)$1.50 million$0.82 millionViewN/AView Earnings Details
3/24/2015($0.10)($0.07)$0.80 million$1.93 millionViewN/AView Earnings Details
11/10/2014($0.09)($0.08)$1.51 million$2.79 millionViewN/AView Earnings Details
8/11/2014($0.09)($0.05)$0.80 million$1.40 millionViewN/AView Earnings Details
5/12/2014($0.09)($0.08)$0.80 million$0.90 millionViewN/AView Earnings Details
3/26/2014($0.08)$0.13$0.50 million$1.38 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.90)($0.90)$0.80 million$0.31 millionViewN/AView Earnings Details
8/12/2013Q2 2013($1.30)($1.70)$0.80 million$0.60 millionViewN/AView Earnings Details
5/3/2013Q1 2013($1.00)$0.90 millionViewN/AView Earnings Details
2/26/2013Q4 2012($0.80)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.70)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.90)ViewN/AView Earnings Details
5/14/2012Q1 2012($1.30)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.85)ViewN/AView Earnings Details
11/14/2011Q3 2011$2.00ViewN/AView Earnings Details
8/12/2011Q2 2011($2.00)($2.00)ViewN/AView Earnings Details
5/13/2011Q1 2011($2.00)($2.00)ViewN/AView Earnings Details
11/12/2010Q3 2010($2.00)($2.00)ViewN/AView Earnings Details
8/13/2010Q2 2010($2.00)($2.00)ViewN/AView Earnings Details
5/17/2010Q1 2010($2.00)ViewN/AView Earnings Details
4/1/2010Q4 2009($2.00)ViewN/AView Earnings Details
11/13/2009Q3 2009($2.00)ViewN/AView Earnings Details
8/14/2009Q2 2009($2.00)ViewN/AView Earnings Details
5/15/2009Q1 2009($2.00)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.60)ViewN/AView Earnings Details
5/16/2008Q1 2008($2.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Soligenix (NASDAQ:SNGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Soligenix (NASDAQ SNGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.03%
Institutional Ownership Percentage: 13.74%
Insider Trading History for Soligenix (NASDAQ:SNGX)
Institutional Ownership by Quarter for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ SNGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2017Spa EssetifinInsiderBuy293,510$2.12$622,241.20View SEC Filing  
5/8/2017Randal J KirkMajor ShareholderSell160,968$3.12$502,220.16View SEC Filing  
12/16/2016Christopher J SchaberCEOBuy15,804$3.16$49,940.6425,095View SEC Filing  
12/16/2016Marco Maria BrugheraDirectorBuy2,000$3.16$6,320.002,750View SEC Filing  
12/23/2015Jerome B ZeldisDirectorBuy2,500$1.27$3,175.0069,166View SEC Filing  
12/22/2015Christopher J SchaberCEOBuy10,000$1.29$12,900.0085,761View SEC Filing  
12/22/2014Joseph Michael WaruszCFOBuy8,265$1.21$10,000.65View SEC Filing  
6/25/2013Christopher J SchaberCEOBuy9,523$1.05$9,999.15View SEC Filing  
6/25/2013Keith L BrownlieDirectorBuy19,047$1.05$19,999.35View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Soligenix (NASDAQ SNGX) News Headlines

Source:
DateHeadline
Soligenix Inc’s (NASDAQ:SNGX) Shift From Loss To ProfitSoligenix Inc’s (NASDAQ:SNGX) Shift From Loss To Profit
finance.yahoo.com - May 25 at 5:57 PM
SNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola VaccineSNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola Vaccine
finance.yahoo.com - May 23 at 5:40 PM
Soligenix, Inc. (SNGX) Forecasted to Earn FY2018 Earnings of ($1.10) Per ShareSoligenix, Inc. (SNGX) Forecasted to Earn FY2018 Earnings of ($1.10) Per Share
www.americanbankingnews.com - May 16 at 8:07 AM
-$0.28 EPS Expected for Soligenix, Inc. (SNGX) This Quarter-$0.28 EPS Expected for Soligenix, Inc. (SNGX) This Quarter
www.americanbankingnews.com - May 15 at 5:14 PM
Zacks Investment Research Weighs in on Soligenix, Inc.s Q2 2018 Earnings (SNGX)Zacks Investment Research Weighs in on Soligenix, Inc.'s Q2 2018 Earnings (SNGX)
www.americanbankingnews.com - May 15 at 8:02 AM
Soligenix (SNGX) Issues  Earnings ResultsSoligenix (SNGX) Issues Earnings Results
www.americanbankingnews.com - May 12 at 11:50 AM
Soligenix (SNGX) Given a $5.00 Price Target at Maxim GroupSoligenix (SNGX) Given a $5.00 Price Target at Maxim Group
www.americanbankingnews.com - May 11 at 6:13 PM
Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial ResultsSoligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 8:18 AM
Soligenix to Present at the NYC Oncology Investor Conference 2018Soligenix to Present at the NYC Oncology Investor Conference 2018
finance.yahoo.com - May 7 at 8:15 AM
Soligenix (SNGX) Upgraded by ValuEngine to "Sell"Soligenix (SNGX) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 2 at 6:12 PM
Soligenix (SNGX) Set to Announce Earnings on WednesdaySoligenix (SNGX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - May 2 at 7:00 AM
Soligenix (SNGX) Coverage Initiated by Analysts at HC WainwrightSoligenix (SNGX) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - April 17 at 11:58 PM
Soligenix (SNGX) Given a $4.00 Price Target at Maxim GroupSoligenix (SNGX) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - April 15 at 3:59 PM
Soligenix (SNGX) Price Target Increased to $5.00 by Analysts at Maxim GroupSoligenix (SNGX) Price Target Increased to $5.00 by Analysts at Maxim Group
www.americanbankingnews.com - April 10 at 5:37 PM
Soligenix (SNGX) Given a $11.00 Price Target by HC Wainwright AnalystsSoligenix (SNGX) Given a $11.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 10 at 5:02 PM
 Analysts Anticipate Soligenix, Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million Analysts Anticipate Soligenix, Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million
www.americanbankingnews.com - March 27 at 7:59 AM
Soligenix (SNGX) Cut to Neutral at HC WainwrightSoligenix (SNGX) Cut to Neutral at HC Wainwright
www.americanbankingnews.com - March 26 at 10:58 AM
Soligenix, Inc. (SNGX) Expected to Announce Earnings of -$0.32 Per ShareSoligenix, Inc. (SNGX) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - March 25 at 8:48 AM
Soligenix, Inc. (SNGX) Granted Orphan Drug Designation from European Commission for RiVax for Prevention of Ricin PoisoningSoligenix, Inc. (SNGX) Granted Orphan Drug Designation from European Commission for RiVax for Prevention of Ricin Poisoning
www.streetinsider.com - March 23 at 8:15 AM
28 Stocks Moving In Thursdays Mid-Day Session28 Stocks Moving In Thursday's Mid-Day Session
feeds.benzinga.com - March 22 at 2:31 PM
Maxim Group Analysts Give Soligenix (SNGX) a $5.00 Price TargetMaxim Group Analysts Give Soligenix (SNGX) a $5.00 Price Target
www.americanbankingnews.com - March 22 at 1:59 PM
Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin PoisoningSoligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning
finance.yahoo.com - March 22 at 8:21 AM
Soligenix (SNGX) Given a $3.00 Price Target at HC WainwrightSoligenix (SNGX) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 16 at 7:47 PM
Soligenix (SNGX) Given a $5.00 Price Target by Maxim Group AnalystsSoligenix (SNGX) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 15 at 5:46 PM
Soligenix Announces Recent Accomplishments And Year-End 2017 Financial ResultsSoligenix Announces Recent Accomplishments And Year-End 2017 Financial Results
finance.yahoo.com - March 15 at 8:12 AM
Zacks: Brokerages Anticipate Soligenix, Inc. (SNGX) Will Post Quarterly Sales of $1.58 MillionZacks: Brokerages Anticipate Soligenix, Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million
www.americanbankingnews.com - March 10 at 10:13 AM
Soligenix (SNGX) & Jazz Pharmaceuticals (JAZZ) Head-To-Head ContrastSoligenix (SNGX) & Jazz Pharmaceuticals (JAZZ) Head-To-Head Contrast
www.americanbankingnews.com - February 26 at 10:48 AM
Financial Contrast: Trillium Therapeutics (TRIL) & Soligenix (SNGX)Financial Contrast: Trillium Therapeutics (TRIL) & Soligenix (SNGX)
www.americanbankingnews.com - February 5 at 9:46 AM
$1.58 Million in Sales Expected for Soligenix, Inc. (SNGX) This Quarter$1.58 Million in Sales Expected for Soligenix, Inc. (SNGX) This Quarter
www.americanbankingnews.com - February 4 at 6:12 AM
Zacks: Brokerages Anticipate Soligenix, Inc. (SNGX) to Announce -$0.32 EPSZacks: Brokerages Anticipate Soligenix, Inc. (SNGX) to Announce -$0.32 EPS
www.americanbankingnews.com - February 2 at 2:22 PM
Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical TrialsSoligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials
www.prnewswire.com - January 25 at 8:02 AM
Windtree Therapeutics (WINT) vs. Soligenix (SNGX) Head-To-Head SurveyWindtree Therapeutics (WINT) vs. Soligenix (SNGX) Head-To-Head Survey
www.americanbankingnews.com - January 18 at 11:18 AM
Head-To-Head Comparison: Soligenix (SNGX) and Osiris Therapeutics (OSIR)Head-To-Head Comparison: Soligenix (SNGX) and Osiris Therapeutics (OSIR)
www.americanbankingnews.com - January 13 at 3:30 AM
Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral MucositisBlog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis
finance.yahoo.com - January 4 at 11:01 AM
Maxim Group Reiterates "$5.00" Price Target for Soligenix (SNGX)Maxim Group Reiterates "$5.00" Price Target for Soligenix (SNGX)
www.americanbankingnews.com - January 3 at 8:00 PM
 Analysts Anticipate Soligenix Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million Analysts Anticipate Soligenix Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million
www.americanbankingnews.com - January 1 at 2:38 PM
Zacks: Brokerages Expect Soligenix Inc. (SNGX) Will Post Earnings of -$0.32 Per ShareZacks: Brokerages Expect Soligenix Inc. (SNGX) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - December 30 at 1:16 PM
Critical Contrast: SIGA Technologies (SIGA) & Soligenix (SNGX)Critical Contrast: SIGA Technologies (SIGA) & Soligenix (SNGX)
www.americanbankingnews.com - December 28 at 7:56 PM
Soligenix (SNGX) Stock Rating Reaffirmed by Maxim GroupSoligenix (SNGX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - December 21 at 4:28 PM
Soligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal RuleSoligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
finance.yahoo.com - December 21 at 3:46 PM
Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal RuleSoligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
www.prnewswire.com - December 21 at 6:26 AM
Analyzing Mirati Therapeutics (MRTX) and Soligenix (SNGX)Analyzing Mirati Therapeutics (MRTX) and Soligenix (SNGX)
www.americanbankingnews.com - December 15 at 9:32 PM
Soligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 MillionSoligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 Million
www.americanbankingnews.com - December 15 at 2:30 PM
Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed LatelyWant To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately
finance.yahoo.com - December 8 at 3:50 PM
Critical Survey: VBI Vaccines (VBIV) versus Soligenix (SNGX)Critical Survey: VBI Vaccines (VBIV) versus Soligenix (SNGX)
www.americanbankingnews.com - December 2 at 9:56 PM
Soligenix Inc. (SNGX) Insider Spa Essetifin Buys 293,510 SharesSoligenix Inc. (SNGX) Insider Spa Essetifin Buys 293,510 Shares
www.americanbankingnews.com - December 1 at 9:02 PM
Soligenix (SNGX) and ContraFect (CFRX) Head-To-Head ContrastSoligenix (SNGX) and ContraFect (CFRX) Head-To-Head Contrast
www.americanbankingnews.com - November 30 at 3:12 AM
Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CASoligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA
finance.yahoo.com - November 27 at 4:13 PM
$1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter$1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter
www.americanbankingnews.com - November 27 at 8:11 AM
Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX)Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX)
www.americanbankingnews.com - November 26 at 1:16 AM

SEC Filings

Soligenix (NASDAQ:SNGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Soligenix (NASDAQ:SNGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Soligenix (NASDAQ SNGX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.